Overview

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bevacizumab